1-10 of 10
Daniel Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT085: A phase 2/3, multicenter trial of lenzilumab and azacitidine in chronic myelomonocytic leukemia: The PREACH-M trial

Devendra Hiwase, David Ross, Steven Lane, Agnes Yong, Kirsty Sharplin, David Yeung, Lisa Butler, Dale Chappell, Cameron Durrant, Timothy Hughes, Daniel Thomas
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT085.
https://doi.org/10.1158/1538-7445.AM2023-CT085
Published: 14 April 2023
View article titled, Abstract CT085: A phase 2/3, multicenter trial of lenzilumab and azacitidine in chronic myelomonocytic leukemia: The PREACH-M trial
Journal Articles

Abstract OT3-17-03: Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results

Daniel Thomas, William Maxwell, Caroline Archer, Anne Rigg, Tamas Hickish, Jo Dent, Laura Pettit, Marianne Dillon, Christy Goldsmith, Mark Verrill, Ludger Barthelmes, Saira Khawaja, Yousef Sharaiha, Mark Davies, Fawaz Arikat, Sahail Khan, Asma Munir, Anita Huws, Simon DavidHenry Holt
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): OT3-17-03.
https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-03
Published: 15 February 2020
View article titled, Abstract OT3-17-03: Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results
Journal Articles

Abstract P3-08-46: Correlation of prognostic indicators based on clinical and pathological features in hormone receptor positive and HER2 receptor negative early breast cancer with the 21 gene assay recurrence score

Marianne Dillon, Adam Yarwood, Daniel Thomas, Wales Cancer Network Breast Clinical Steering Group
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-08-46.
https://doi.org/10.1158/1538-7445.SABCS19-P3-08-46
Published: 15 February 2020
View article titled, Abstract P3-08-46: Correlation of prognostic indicators based on clinical and pathological features in hormone receptor positive and HER2 receptor negative early breast cancer with the 21 gene assay recurrence score
Journal Articles

Abstract A1-23: Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets

Subarna Sinha, Daniel Thomas, Ravindra Majeti, David L. Dill
Journal: Cancer Research
Cancer Res (2015) 75 (22_Supplement_1): A1-23.
https://doi.org/10.1158/1538-7445.TRANSCAGEN-A1-23
Published: 15 November 2015
View article titled, Abstract A1-23: Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets
Journal Articles

Abstract B2-20: Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets

Subarna Sinha, Daniel Thomas, Ravindra Majeti, David L. Dill
Journal: Cancer Research
Cancer Res (2015) 75 (22_Supplement_2): B2-20.
https://doi.org/10.1158/1538-7445.COMPSYSBIO-B2-20
Published: 15 November 2015
View article titled, Abstract B2-20: Deciphering the cancer methylome with Boolean implications to find novel drivers of aberrant DNA methylation and actionable drug targets
Journal Articles

Abstract 3009: ATRX validated as tumor suppressor in a novel mouse model of pediatric and young adult GBM

Carl Koschmann, Alexandra Calinescu, Daniel Thomas, Felipe J. Nunez, Marta Dzaman, Johnny Krasinkiewicz, Rosie Lemons, Neha Kamran, Flor Mendez, Soyeon Roh, David Ferguson, Pedro R. Lowenstein, Maria G. Castro
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3009.
https://doi.org/10.1158/1538-7445.AM2015-3009
Published: 01 August 2015
View article titled, Abstract 3009: ATRX validated as tumor suppressor in a novel mouse model of pediatric and young adult GBM
Journal Articles

Abstract P3-01-01: Can synthetic 2D mammography be used to select patients in whom there is no need to review the digital breast tomosynthesis from which they were constructed? A review of 1871 consecutive mammogram sets of patients presenting symptomatically or for follow

Simon DH Holt, Ali Moalla, Helen R Williams, Khaldoun MY Nadi, Anita M Huws, Amrita Gurung, Daniel Thomas, Yousef M Sharaiha
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-01-01.
https://doi.org/10.1158/1538-7445.SABCS14-P3-01-01
Published: 01 May 2015
View article titled, Abstract P3-01-01: Can synthetic 2D mammography be used to select patients in whom there is no need to review the digital breast tomosynthesis from which they were constructed? A review of 1871 consecutive mammogram sets of patients presenting symptomatically or for follow
Journal Articles

Abstract 995: Loss of ATRX decreases survival and improves response to DNA damaging agents in a novel mouse model of glioblastoma

Carl Koschmann, Alexandra Calinescu, Marta Dzaman, Rosie Lemons, Daniel Thomas, Maria G. Castro, Pedro R. Lowenstein
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 995.
https://doi.org/10.1158/1538-7445.AM2014-995
Published: 01 October 2014
View article titled, Abstract 995: Loss of ATRX decreases survival and improves response to DNA damaging agents in a novel mouse model of glioblastoma
Journal Articles

Abstract A19: The selective targeting of cell survival pathways in leukemia

Daniel Thomas, Jason A. Powell, Michael W. Parker, Paul G. Ekert, Richard B. Lock, David CS Huang, Susie K. Nilsson, Christian Recher, Andrew H. Wei, Mark A. Guthridge
Journal: Cancer Research
Cancer Res (2013) 73 (19_Supplement): A19.
https://doi.org/10.1158/1538-7445.FBCR13-A19
Published: 15 May 2014
View article titled, Abstract A19: The selective targeting of cell survival pathways in leukemia
Journal Articles

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

Kathryn G. Roberts, Amanda M. Smith, Fiona McDougall, Helen Carpenter, Martin Horan, Paolo Neviani, Jason A. Powell, Daniel Thomas, Mark A. Guthridge, Danilo Perrotti, Alistair T.R. Sim, Leonie K. Ashman, Nicole M. Verrills
Journal: Cancer Research
Cancer Res (2010) 70 (13): 5438–5447.
https://doi.org/10.1158/0008-5472.CAN-09-2544
Published: 30 June 2010
View article titled, Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers
Open the PDF for Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT<sup>+</sup> Cancers in another window
Includes: Supplementary data